MyFinsight
Home
Blog
About
Contact
Download
Download image
Net proceeds from
issuance of common stock...
$4,004,715
Net cash provided by
financing activities
$4,004,715
Net change in cash
$1,718,064
Canceled cashflow
$2,286,651
Prepaid expenses and
other
-$255,660
Accounts payable,
accrued expenses and...
$73,762
Share-based expense
$64,787
Net cash used in
operating activities
-$2,286,651
Canceled cashflow
$394,209
Net loss
-$2,680,860
Back
Back
Cash Flow
source: myfinsight.com
Xenetic Biosciences, Inc. (XBIO)
Xenetic Biosciences, Inc. (XBIO)